STEAP3 and nonpapillary renal cell carcinoma: Analysis of classical immune checkpoints showed that STEAP3 was highly correlated with SIGLEC15, suggesting that ccRCC patients with high STEAP3 expression may benefit from the inhibitor against SIGLEC15.